MARLBOROUGH, Mass.,
May 11, 2018 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII) announced today that it
has entered into a research collaboration with Iovance
Biotherapeutics to evaluate the potential synergies with RXi's
novel sd-rxRNA therapeutic compounds and Iovance's autologous cell
therapy based on tumor-infiltrating lymphocytes (TILs) for the use
in the treatment of cancer.
Logo- http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
Dr. Geert Cauwenbergh,
President and CEO of RXi Pharmaceuticals, stated:
"Iovance is the leading company developing novel cancer
immunotherapies based on tumor-infiltrating lymphocyte (TIL)
technology. Our agreement will allow Iovance to explore their
proprietary TIL technology and our proprietary sd-rxRNA technology.
Under this research collaboration, we will further investigate and
expand the recently published data with TIL and sd-rxRNA products,
which demonstrated potentially enhanced tumor killing activity of
TIL." He added that: "As such, we may be able to improve potency of
the TIL product and also possibly broaden the applicability of TIL
in other tumors types. We see this new research collaboration with
the highly experienced Iovance team using TIL, as a major step to
advance life-saving treatment approaches for solid tumors, a space
where there is still a dire need for improved therapies for these
patients."
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's discovery and
research efforts are focused on developing sd-rxRNA therapeutic
compounds to be used with an Adoptive Cell Transfer (ACT) approach.
This process uses immune cells, such as T-lymphocytes that are
isolated from the patient or retrieved from allogeneic immune cell
banks, and then expanded and in some cases processed to express
tumor-binding receptors. Our approach introduces a new and
important step in ex-vivo processing of the immune
cells where sd-rxRNA is used to eliminate the expression of
immunosuppressive receptors or proteins from the therapeutic immune
cells, making them less sensitive to tumor resistance mechanisms
and thus improving their ability to destroy the tumor cells.
Essentially, we aim to maximize the power of our sd-rxRNA
therapeutic compounds by weaponizing therapeutic immune effector
cells to attack cancer and ultimately provide patients battling
terminal cancers with a powerful new treatment option that goes
beyond current treatment modalities.
For additional information, visit the Company's
website, www.rxipharma.com.
Forward-Looking Statements of RXi Pharmaceuticals
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our expectation regarding closing of the offering, our
ability to successfully develop RXI-109, Samcyprone™, RXI-762,
RXI-804 and our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact RXi Pharmaceuticals Corporation
Tamara McGrillen
Tel: +1 508-929-3646
Email: tmcgrillen@rxipharma.com
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-enters-into-material-transfer-agreement-with-iovance-biotherapeutics-to-study-its-self-delivering-rnai-technology-for-the-advancement-of-immuno-oncology-therapeutics-with-iovances-tumor-infiltrating-lymphocyte-300646864.html
SOURCE RXi Pharmaceuticals Corporation